Core Insights - Regentis Biomaterials Ltd. is expanding its U.S. clinical site network to enhance its infrastructure for ongoing and future clinical programs [1] - The company has surpassed 50% patient enrollment in its pivotal Phase III study of GelrinC® for knee cartilage repair [1] - GelrinC is positioned to transform the cartilage repair market with its off-the-shelf regenerative products [1] Company Developments - The expansion of clinical sites is expected to accelerate patient enrollment in the ongoing Phase III study [1] - The new sites will also support future clinical programs beyond the current study [1] Industry Impact - GelrinC is anticipated to significantly impact the cartilage repair market by providing innovative regenerative solutions [1]

Core Insights - GelrinC-treated patients showed layered cartilage architecture similar to native hyaline cartilage, indicating true biological cartilage regeneration rather than just defect filling [1] - GelrinC limits fibrotic tissue overgrowth, which supports smoother joint motion and preserves natural biomechanics [1] Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions [1] - The company announced new long-term imaging data from a completed European clinical trial of GelrinC® [1] Clinical Trial Results - The clinical trial demonstrated that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage [1]

Core Insights - Regentis Biomaterials Ltd. has published long-term follow-up results from its Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage, marking a significant advancement in cartilage repair technology [1] - The study utilized the MOCART quantitative standard to measure cartilage regeneration, establishing GelrinC as a leader in long-term durable cartilage repair [1] - Two years post-treatment, the repaired cartilage demonstrated morphology very close to that of normal healthy cartilage, indicating the long-term durability and competitive superiority of GelrinC in the cartilage repair market [1] Company Developments - GelrinC is already approved in Europe and is currently undergoing a pivotal Phase III study with the U.S. FDA [1] - The data presented reinforces Regentis's position in the regenerative medicine sector, focusing on innovative tissue repair solutions [1]

Core Insights - The article highlights the issuance of a new patent for GerlinC, a ready-to-use liquid formulation that enhances efficiency and focus for surgeons, leading to a 10-minute procedure [1] - Regentis Biomaterials Ltd. has a robust intellectual property portfolio with 35 issued patents globally [1] - GerlinC is currently undergoing a pivotal FDA trial and has received regulatory approval in the EU, marking it as the world's first off-the-shelf regenerative treatment for knee cartilage repair [1] Company Developments - The U.S. Patent and Trademark Office granted a patent for "Organic Solvent Free Compositions Compromising Protein-Polymer Conjugates and Uses Thereof," which pertains to the production processes of GerlinC that eliminate the use of organic solvents [1] - The focus on innovative tissue repair solutions positions Regentis as a key player in the regenerative medicine sector [1]

Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing innovative tissue repair solutions aimed at restoring health and enhancing the quality of life for patients [5] - The company's primary focus is on orthopedic treatments utilizing its Gelrin platform, which is based on degradable hydrogel implants to regenerate damaged or diseased tissue [5] Initial Public Offering (IPO) Details - The company announced the closing of its IPO, offering 1,250,000 ordinary shares at a public offering price of $8.00 per share, resulting in aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses [1][2] - The ordinary shares began trading on the NYSE American LLC under the symbol "RGNT" on December 4, 2025 [2] - The company granted underwriters a 45-day option to purchase up to an additional 187,500 ordinary shares to cover over-allotments [1] Use of Proceeds - The net proceeds from the offering will primarily be used for development activities, including the completion of a pivotal trial and preparation for the PMA submission for GelrinC, as well as for corporate purposes such as repaying certain debt and deferred compensation payments [2] Product Information - GelrinC is the company's lead product candidate, designed as a cell-free, off-the-shelf hydrogel that serves as a temporary implant for treating painful injuries to articular knee cartilage [5] - GelrinC has received a Conformité Européene (CE) mark in Europe, allowing the company to initiate commercialization efforts in that region while also focusing on obtaining FDA approval in the United States [5]

Core Points - Regentis Biomaterials Ltd. has announced the pricing of its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming for gross proceeds of $10 million before expenses [1][3] - The ordinary shares are set to begin trading on the NYSE American under the symbol "RGNT" on December 4, 2025, with the offering expected to close around December 5, 2025 [2] - The company plans to utilize the net proceeds primarily for development activities, including completing its pivotal trial and preparing for PMA submission for its product GerlinC, as well as for corporate purposes such as debt repayment [3] Company Overview - Regentis Biomaterials Ltd. focuses on regenerative medicine, specifically developing innovative tissue repair solutions to enhance patient health and quality of life [6] - The company's lead product, GelrinC, is a cell-free hydrogel designed for treating articular knee cartilage injuries and has received CE mark approval in Europe [6] - Regentis aims to commercialize GelrinC in Europe while also working towards obtaining FDA approval in the United States [6]

Group 1 - The U.S. IPO market saw two small IPOs and three SPACs listed last week, with five IPOs and four SPACs filing initial applications [1][2] - Off The Hook YS (OTH) priced its reduced IPO at the lower end of the range, raising $15 million with a market cap of $95 million, but its stock fell by 8% [1] - Phaos Technology (POAS) also priced its IPO at the lower end, raising $14 million with a market cap of $114 million, and its stock remained flat [1] Group 2 - Three SPACs completed pricing last week: Alussa Energy Acquisition II (ALUB.U) raised $250 million targeting energy and power infrastructure, Evolution Global Acquisition (EVOXU) raised $210 million focusing on critical minerals, and Blueport Acquisition (BPACU) raised $50 million [2] - Five companies filed for IPOs last week, including Klook (KLK) seeking $400 million, Grayscale (GRAY) aiming for $100 million, and Reed's (REED) targeting $10 million [2][4] Group 3 - Upcoming IPOs include Central Bancompany (CBC) planning to raise $400 million with a market cap of $5.365 billion, and Gloo Holdings (GLOO) aiming for $100 million with a market cap of $801 million [5][7] - Regentis Biomaterials (RGNT) plans to raise $11 million with a market cap of $62 million, focusing on a hydrogel implant for knee cartilage pain [6][7]

Summary of Key Points Core Viewpoint - The article discusses recent IPO activities, highlighting six new stocks that raised approximately $540 million, along with upcoming IPO plans for four companies in the near future [1]. Group 1: Recent IPOs - Six new stocks were listed last week, raising about $540 million in total [1]. - Off The Hook (OTH) raised $15 million by issuing 3.75 million shares at $4 each, down from an initial plan of 5 million shares [1]. - Phaos Technology (POAS) raised $14.4 million by issuing 3.6 million shares at $4 each [1]. - Caring Brands (CABR) raised $4 million by issuing 1 million shares at $4 each [1]. - SPAC Evolution Global Acquisition (EVOXU) raised $210 million, Blueport Acquisition (BPACU) raised $50 million, and Alussa Energy Acquisition II (ALUBU) raised $250 million [1]. - Twelve companies submitted IPO applications, including five from China, with four being blank check companies [1]. Group 2: Upcoming IPOs - Gloo Holdings, Inc. plans to go public on November 19, 2025, on NASDAQ under the ticker GLOO, aiming to raise approximately $109 million by issuing 9.1 million shares at $10 to $12 each [3][4]. - Regentis Biomaterials Ltd. plans to list on NYSE MKT on November 19, 2025, under the ticker RGNT, seeking to raise about $12 million by issuing 1 million shares at $10 to $12 each [5][6]. - Central Bancompany, Inc. plans to go public on November 20, 2025, on NASDAQ under the ticker CBC, aiming to raise approximately $427 million by issuing 17.78 million shares at $21 to $24 each, with reported revenue of $735 million and net profit of $283 million for the nine months ending September 30, 2025 [7][8]. - Libera Gaming Operations, Inc. plans to list on NASDAQ on November 21, 2025, under the ticker LBRJ, aiming to raise about $7.5 million by issuing 1.25 million shares at $4 to $6 each, with revenue of $52.52 million and net profit of $4.16 million for the twelve months ending October 31, 2024 [9][10].

As filed with the Securities and Exchange Commission on October 24, 2025. Registration No. 333-285692 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 6 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REGENTIS BIOMATERIALS LTD. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organ ...

As filed with the Securities and Exchange Commission on September 29, 2025. Registration No. 333-285692 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REGENTIS BIOMATERIALS LTD. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or org ...